AscellaHealth Partnership With Abeona Therapeutics Highlights The Launch Commercialization Of ZEVASKYN, An FDA-Approved Cell-Based Gene Therapy

BERWYN, Pa., July 29, 2025 (GLOBE NEWSWIRE) -- AscellaHealth, a global partner delivering customizable solutions to support the specialty pharmaceutical industry, highlights the value of its HUB partnership with Abeona Therapeutics Inc. (NASDAQ:ABEO) in the successful pre-and-post launch commercialization of ZEVASKYN™, an FDA-approved cell-based gene therapy. Working as a collaborative partner, AscellaHealth designed and executed patient-centric, end-to-end solutions to address unique clinical, operational and reimbursement needs for a new-to-world autologous cell-based gene therapy. By focusing on the requirements of patients throughout the entire therapeutic journey, AscellaHealth led the collaborative effort to build and launch AbeonaAssist™, a highly customized patient support program that creates a seamless experience for patients, caregivers and healthcare providers.

"Abeona's groundbreaking cell-based gene therapy demanded a HUB partner who could build tailored infrastructure from the ground up," said William White, Vice President of Market Access at Abeona Therapeutics. "AscellaHealth's comprehensive expertise in navigating this complex journey, from patient and provider engagement to optimizing reimbursement for this first-of-its-kind treatment, made them the unequivocal partner of choice. Since launch, their unwavering commitment to a patient-centric model, which perfectly aligns with our program's vision, has proven invaluable."

Bill Oldham, Chairman and President, AscellaHealth, says, "We value our strategic partnership with Abeona which is built upon an aligned vision, a foundation of shared goals and a clear understanding of what can be achieved through collaboration. Together, we have created synergies that not only benefit both organizations, but most importantly, patient access to treatment and optimized clinical outcomes. Abeona epitomizes our description of an ideal partner that is committed to open communications, trust and transparency."